Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II heterologous H5N1 booster vaccination follow-up study
2007-002894-30Phase 2Completed
- Sponsor
- Baxter International Inc.
- Start
- Aug 2007
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inactivated Vero cell based whole virus influenza A/H5N1 in avian influenza (HPAI), sponsored by Baxter International Inc. Primary endpoint: Primary immunogenicity endpoint. Started Aug 2007; status: completed.
02
Drugs
inactivated Vero cell based whole virus influenza A/H5N1
03
Conditions
avian influenza (HPAI)
Beyond the preview
Go deeper on 2007-002894-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002894-30.